XON - Intrexon Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.60
+0.25 (+3.40%)
At close: 4:00PM EDT

7.60 0.00 (0.00%)
After hours: 4:45PM EDT

Stock chart is not supported by your current browser
Previous Close7.35
Open7.38
Bid7.58 x 3000
Ask7.91 x 800
Day's Range7.23 - 7.68
52 Week Range3.95 - 19.94
Volume1,518,178
Avg. Volume2,703,504
Market Cap1.227B
Beta (3Y Monthly)1.43
PE Ratio (TTM)N/A
EPS (TTM)-3.86
Earnings DateAug 7, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.67
Trade prices are not sourced from all markets
  • Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)
    PR Newswire14 hours ago

    Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)

    GERMANTOWN, Md., June 26, 2019 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the first patient has been dosed with PRGN-3006, a first-in-class investigational therapy using Precigen's non-viral UltraCAR-T™ therapeutic platform. PRGN-3006 UltraCAR-T is an autologous chimeric antigen receptor T (CAR-T) cell therapy under investigation for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or higher risk myelodysplastic syndrome (MDS) (clinical trial identifier: NCT03927261).

  • Do Options Traders Know Something About Intrexon (XON) Stock We Don't?
    Zacks2 days ago

    Do Options Traders Know Something About Intrexon (XON) Stock We Don't?

    Investors need to pay close attention to Intrexon (XON) stock based on the movements in the options market lately.

  • Intrexon Up on Striking 100M Cannabinoid Deal With Surterra
    Zacks8 days ago

    Intrexon Up on Striking 100M Cannabinoid Deal With Surterra

    Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.

  • Why Intrexon Stock Popped Today
    Motley Fool9 days ago

    Why Intrexon Stock Popped Today

    A big deal with a medical cannabis company provided a spark for Intrexon.

  • Benzinga9 days ago

    Intrexon Strikes $100M Partnership With Surterra For Cannabinoid Production

    Intrexon Corporation (NASDAQ: XON) announced a 0 million partnership with Surterra Wellness to advance its cannabinoid production. The companies will join forces to push forward Surterra's cannabinoid production at a cost-effective, industrial scale utilizing Intrexon's proprietary yeast fermentation platform. Need more cannabis news?

  • PR Newswire9 days ago

    Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production

    Exclusive Global Agreement to Transform Surterra's Ability to Produce Specific Cannabinoids to Meet Growing Demand, Boost Innovation and Product Development BUDAPEST, Hungary and ATLANTA , June 18, 2019 ...

  • Markit9 days ago

    See what the IHS Markit Score report has to say about Intrexon Corp.

    Intrexon Corp NASDAQ/NGS:XONView full report here! Summary * Bearish sentiment is high and has been increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for XON with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting XON. Sentiment has worsened and traders added to their bearish short positions on June 14. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold XON had net inflows of $1.84 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • PR Newswire14 days ago

    Intrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference

    GERMANTOWN, Md. , June 13, 2019 /PRNewswire/ --  Intrexon Corporation  (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...

  • GuruFocus.com17 days ago

    Intrexon Corp (XON) CEO Randal J Kirk Bought $2.5 million of Shares

    CEO of Intrexon Corp (NASDAQ:XON) Randal J Kirk bought 483,268 shares of XON on 06/07/2019 at an average price of $5.24 a share.

  • GuruFocus.com17 days ago

    Weekly CEO Buys Highlight

    Details the CEO buys this past week for the following companies: Capri Holdings, Odonate Therapeutics, Freeport-McMoRan, Intrexon and American Airlines

  • Intrexon (XON) Up 24.7% Since Last Earnings Report: Can It Continue?
    Zacks19 days ago

    Intrexon (XON) Up 24.7% Since Last Earnings Report: Can It Continue?

    Intrexon (XON) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GuruFocus.com23 days ago

    Intrexon Corp (XON) CEO Randal J Kirk Bought $998,306 of Shares

    CEO of Intrexon Corp (NASDAQ:XON) Randal J Kirk bought 203,321 shares of XON on 06/04/2019 at an average price of $4.91 a share.

  • Oxitec Successfully Completes First Field Deployment of 2nd Generation Friendly™ Aedes aegypti Technology
    PR Newswire24 days ago

    Oxitec Successfully Completes First Field Deployment of 2nd Generation Friendly™ Aedes aegypti Technology

    CAMPINAS, Brazil, June 3, 2019 /PRNewswire/ -- Oxitec Ltd., a UK-based biotechnology company specializing in developing novel, environmentally-sustainable pest management solutions, today announced the successful completion of the first field trial in Brazil of its 2nd Generation Friendly™ Aedes aegypti technology. In partnership with the municipal vector control authorities in the city of Indaiatuba, the pilot project demonstrated the new strain's effectiveness in suppressing populations of the Aedes aegypti mosquito - the primary vector of dengue, Zika, chikungunya and yellow fever - in four densely populated urban communities across the city.

  • Intrexon Announces Advances in Non-Browning GreenVenus™ Romaine Lettuce
    PR Newswire24 days ago

    Intrexon Announces Advances in Non-Browning GreenVenus™ Romaine Lettuce

    DAVIS, Calif., June 3, 2019 /PRNewswire/ -- Intrexon Corporation (XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it is advancing GreenVenus™ Romaine lettuce to commercial trials.

  • Benzinga24 days ago

    Notable Insider Buys This Past Week: Coty, Zillow and More

    Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. Zillow Group Inc (NASDAQ: Z) had a director return for more notable indirect share purchases this past week. Zillow's new business in buying and selling homes has helped boost its revenue.

  • Benzinga27 days ago

    Intrexon CEO Made Big Open-Market Bets In May

    Biotechnology company Intrexon Corp (NASDAQ: XON ) CEO Randal Kirk made five bundles of large purchases of the company's stock over the month of May. Recent trades listed below, courtesy of GuruFocus: ...

  • GuruFocus.com27 days ago

    Intrexon Corp (XON) CEO Randal J Kirk Bought $2.4 million of Shares

    CEO of Intrexon Corp (NASDAQ:XON) Randal J Kirk bought 495,271 shares of XON on 05/30/2019 at an average price of $4.75 a share.

  • Fibrocell Up on FDA Designation for Gene Therapy Candidate
    Zacks28 days ago

    Fibrocell Up on FDA Designation for Gene Therapy Candidate

    Fibrocell's (FCSC) gene therapy for a genetic skin disorder gets Regenerative Medicine Advanced Therapy designation, which expedites development process.

  • GlobeNewswire29 days ago

    Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB

    EXTON, Pa., May 29, 2019 -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective.

  • PR Newswirelast month

    Intrexon to Participate in 2019 BIO International Convention

    GERMANTOWN, Md. , May 28, 2019 /PRNewswire/ --   Intrexon Corporation  (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...